secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001104659-26-054943
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute sunRIZE Phase 3 misses primary endpoint; CGM analyses show nominal hypoglycemia reduction
--------------------------------------------------------------------------------

- Primary endpoint (hypoglycemia events by SMBG) not met; secondary CGM endpoint not statistically significant at Week 24/EOT.
- CGM analyses showed nominal significance: >50% reduction in time-in-hypoglycemia (FAS), ~60-80% (PPS) vs placebo across timepoints.
- OLE: all 59 completers enrolled, 57 continue; up to 24 months exposure; reduced background SOC, many on ersodetug monotherapy.
- FDA Type B meeting (Mar 17, 2026) acknowledged primary endpoint challenges; requested comprehensive data submission to inform next steps.
- Company believes data show target engagement and therapeutic potential; seeking alignment with FDA on path to approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465926054943/0001104659-26-054943-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465926054943/tm2613408d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-054943

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer